Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Search
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
How we Support Grass Roots Innovation
How we Support Grass Roots Innovation
Evolution of Anticoagulation Timeline
Chronic Kidney Disease
Chronic Kidney Disease
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Introducing Ingelvac Provenza™ | Boehringer Ingelheim US
Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.
Mental Health
Mental Health
Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E
Queen Latifah and Bernie Williams star
Let’s find CKD
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Shelter Bowl: These pets looking for a new home were the big winners
Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Meet our 2023 HBA Luminary award winner honored for inspiring others
Meet our 2023 HBA Luminary award winner honored for inspiring others
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US
BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.
BI Cares Financial Contributions Program: Strengthening Communities
BI Cares Financial Contributions Program: Strengthening Communities
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand